Evaluation of Glucose Metrics in Adults with Type 1 Diabetes Switching to Insulin Glargine 300 U/mL: A Retrospective, Propensity-Score Matched Study-Reference-Cited by-同舟云学术

Evaluation of Glucose Metrics in Adults with Type 1 Diabetes Switching to Insulin Glargine 300 U/mL: A Retrospective, Propensity-Score Matched Study

Published:2024-07-01 Issue:7 Volume:26 Page:488-493
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Charleer Sara¹^ORCID,Fieuws Steffen²,De Block Christophe³^ORCID,Bolsens Nancy³,Nobels Frank⁴,Mikkelsen Kristian⁵,Mathieu Chantal¹,Gillard Pieter¹⁶^ORCID

Affiliation:

1. Department of Endocrinology, University Hospitals Leuven–KU Leuven, Leuven, Belgium.

2. Interuniversity Institute for Biostatistics and Statistical Bioinformatics, KU Leuven and University of Hasselt, Leuven, Belgium.

3. Department of Endocrinology-Diabetology-Metabolism, University Hospital Antwerp - University of Antwerp, Antwerp, Belgium.

4. Department of Endocrinology, OLV Hospital Aalst, Aalst, Belgium.

5. Sanofi-Aventis Denmark A/S, Copenhagen, Denmark.

6. Fonds Wetenschappelijk Onderzoek (FWO), Brussels, Belgium.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/dia.2023.0371

Reference19 articles.

1. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement

2. Insulin analogues in type 1 diabetes mellitus: getting better all the time

3. New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

4. Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections

5. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes